帕利哌酮治疗精神分裂症及其对生活质量的影响被引量：2

Effect of Paliperidone on Schizophrenia and Its Influence on Quality of Life

下载PDF

导出

摘要目的探讨帕利哌酮对精神分裂症患者的疗效、安全性和生活质量的影响,为临床应用提供参考。方法将符合CCMD-Ⅲ精神分裂症诊断标准的住院患者99例随机分为:实验组48例给予帕利哌酮缓释片治疗,对照组51例给予齐拉西酮治疗,观察8周。采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)和相关实验室检查评定副反应,用生活质量综合评定量表(GQOLI-74)评定生活质量。结果治疗后两组患者各周PANSS比较差异无统计学意义。但实验组锥体外系症状(EPS)、肝功能异常患者明显少于对照组(χ2=4.01,4.99;P<0.05),实验组病人社会功能改善、躯体功能恢复明显优于对照组(t=2.08,2.14;P<0.05)。结论帕利哌酮在提高精神分裂症患者生活质量方面的效果明显优于齐拉西酮。 Objective To investigate the efficacy and safety of paliperidone on schizophrenia and its influence on quality of life ,and provide the reference for clinical application .Methods According to CCMD -III diagnostic criteria of schizophrenia , inpatients were randomly divided into two groups：48 cases in experimental group given paliperidone extended -release tablets treatment ,51 cases in the control group were given ziprasidone treatment .Observation was during for 8 weeks.The positive and negative syndrome scale （ PANSS） was used to assessed the efficacy,Tredtment Emergent Symptoms Scale（TESS）and related laboratory assessment for side effects,with the comprehensive quality of life scale （ GQOLI-74 ） assessing quality of life .Results After treatment , PANSS in two patients showed no statistical significante difference each week .But in the experimental group ,EPS and patients with abnormal liver function were significant-ly less than those of the control group （χ2 =4.01,4.99;P〈0.05）,the social function and recovery of physical function were more im-proved in experimental group than in control group （t=2.08,2.14;P〈0.05）.Conclusion The effect of paliperidone in improving the quality of life in patients with schizophrenia is superior to that of ziprasidone .

作者张晓明

机构地区河北省唐山市第五医院

出处《中国健康心理学杂志》 2014年第8期1133-1135,共3页 China Journal of Health Psychology

关键词精神分裂症生活质量帕利哌酮齐拉西酮 Schizophrenia Quality of life Paliperidone Risperidone

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献10

1中华医学会精神科学会.中国精神疾病分类方案与诊断标准[M].济南:山东科学技术出版社,2001:4.
2成军,郭素芹,李强,杜海霞.首发精神分裂症患者生活质量对照研究[J].健康心理学杂志,2004,12(2):111-114. 被引量：5
3中华医学会精神分会.中国精神疾病防治指南[M].北京:北京大学医学出版社,2010:25.
4Kramer M, simpson C, Maciulis V, et al. Paliperidone extended - re- lease tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double - blind, placebo - controlled study [ J ]. J Clin PsychopharmacoIogy ,2007,27 ( 1 ) :6-14.
5Fowler J A, Bettinger T L, Argo T R. Paliperidone extended release tablets for the acute and maintenance treatment of schizo - phrenia[ J ]. Clin Ther,2008,30 (2) :231-248.
6Canuso C M, Dirks B, Carothers J. Randomized, double - blind, place- bo - controlled study of paliperidone extended - release and quetiapine in inpatients with recently exacerbated schizophrenia[ J]. Am J Psychi- atry ,2009,166(6) :691-701.
7Fowler J A, Bettinger T L, Argo T R. Pallperidane extended - release tabletsieor the acute and maintenance treatment of schizophrenia [ J ]. Clin Ther,2008,30(2) :231-248.
8刘海军,刘忠.帕利哌酮对精神分裂症患者社会功能影响的随访研究[J].中国健康心理学杂志,2012,20(6):803-805. 被引量：9
9李和军,刘忠,王立娟.帕利哌酮治疗精神分裂症疗效观察[J].中国健康心理学杂志,2011,19(3):276-278. 被引量：17
10王旸,曹昱,张艳.帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究[J].精神医学杂志,2009,22(6):415-419. 被引量：91

二级参考文献40

1Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition[J]. Am J Psychiatry, 2004, 161 (2) : 1 -56.
2Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia [ J]. Can J Psychiatry, 2005, 50 (1):7-57.
3Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia[ J ]. Drags, 1994, 48(2) : 253 -273.
4Revill P, Serradell N, Bolos J. Paliperidone: antipsychotie agent treatment of bipolar disorder dual dopamine D2/5 - HT2A receptor antagonist[ J ]. Drugs Future, 2006, 31 (7) : 579 - 584.
5Herbert YM, William VB, Isaax FN, et al. Efficacy and tolerability of oral paliperidone extended- release tablets in the treatment of acute schizophrenia: pooled data from three 6 - week, placebo- controlled studies [ J]. J Clin Psychiatry, 2008, 69(5) : 817 -829.
6Tzimos A, Lramer M, Ford L, et al. A six - week placebo - controlled study on the safety and tolerability of flexible doses of oral paliperidone extended - release tablets in the treatment of schizophrenia in elderly patients [ C ]. 159^th Annual Meeting of the American Psychiatry Association, 2006, 183.
7Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended - release tablets : a 6 - week placebo - controlled trial[ J]. Schizophrenia Research, 2007, 90( 1 ) : 147 - 161.
8Lehman AF, Buchanan RW, Dickerson FB, et al. Evidence - based treatment for schizophrenia [ J ]. Psyehiatr Clin North Am, 2003, 26. 939- 954.
9Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia[J]. Expert Rev Neurother, 2004, 4: 705- 723.
10Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions[J]. Schizophr Bull, 2002, 28: 105- 109.